$0.97
Equillium is a biotechnology business based in the US. Equillium shares (EQ) are listed on the NASDAQ and all prices are listed in US Dollars. Equillium employs 45 staff and has a trailing 12-month revenue of around $42.6 million.
Our top picks for where to buy Equillium stock
How to buy Equillium stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – EQ. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Equillium stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Equillium stock price (NASDAQ: EQ)
Use our graph to track the performance of EQ stocks over time.Equillium shares at a glance
Latest market close | $0.97 |
---|---|
52-week range | $0.45 - $3.25 |
50-day moving average | $0.80 |
200-day moving average | $1.25 |
Wall St. target price | $6.75 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.23 |
Is it a good time to buy Equillium stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Equillium price performance over time
Historical closes compared with the close of $0.971 from 2024-09-03
1 week (2024-08-29) | -10.09% |
---|---|
1 month (2024-08-05) | 52.79% |
3 months (2024-06-05) | 13.20% |
6 months (2024-03-05) | -56.65% |
1 year (2023-09-05) | 18.41% |
---|---|
2 years (2022-09-02) | -64.95% |
3 years (2021-09-03) | 6.02 |
5 years (2019-09-05) | 4.0316 |
Equillium financials
Revenue TTM | $42.6 million |
---|---|
Gross profit TTM | $15.8 million |
Return on assets TTM | -11.95% |
Return on equity TTM | -33.67% |
Profit margin | -19.51% |
Book value | $0.63 |
Market Capitalization | $37.9 million |
TTM: trailing 12 months
Equillium share dividends
We're not expecting Equillium to pay a dividend over the next 12 months.
Equillium share price volatility
Over the last 12 months, Equillium's shares have ranged in value from as little as $0.45 up to $3.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Equillium's is 1.839. This would suggest that Equillium's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Equillium overview
Equillium, Inc. , a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc.
Frequently asked questions
nullWhat percentage of Equillium is owned by insiders or institutions?
Currently 36.247% of Equillium shares are held by insiders and 19.996% by institutions. How many people work for Equillium?
Latest data suggests 45 work at Equillium. When does the fiscal year end for Equillium?
Equillium's fiscal year ends in December. Where is Equillium based?
Equillium's address is: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 What is Equillium's ISIN number?
Equillium's international securities identification number is: US29446K1060 What is Equillium's CUSIP number?
Equillium's Committee on Uniform Securities Identification Procedures number is: 29446K106
More guides on Finder
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
6 stocks like Nvidia you need to consider
Advanced Micro Devices (AMD), Intel Corporation (INTC) and Qualcomm Inc (QCOM) are top stocks like Nvidia. See our full list here.
-
Frec review 2024: Low-cost direct indexing and individual stock trading
A deep dive into the highlights and limitations of Frec.
-
Public vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Streitwise review
An online REIT with low fees, consistent dividends and a stable portfolio, but a brief track record.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question